Zynerba Pharmaceuticals, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Zynerba Pharmaceuticals, Inc. formerly operated as a clinical-stage specialty pharmaceutical organization, dedicated to advancing cannabinoid-based therapies. The company concentrated on developing pharmaceutically manufactured, transdermally delivered treatments for a range of rare and near-rare neuropsychiatric conditions. Its principal investigational product was Zygel, a synthetic cannabidiol formulated as a permeation-enhanced gel designed for application through the skin. Zygel was under development for disorders such as Fragile X syndrome, 22q11.2 deletion syndrome, and autism spectrum disorder, with the lead program for Fragile X syndrome having received Fast Track and Orphan Drug designations. Zynerba Pharmaceuticals, Inc. became a wholly-owned subsidiary of Harmony Biosciences Holdings, Inc. following an acquisition completed in October 2023. The entity was established in 2007 and maintained its corporate headquarters in Devon, Pennsylvania.
Company News
22q11.2 Deletion Syndrome Market Research Report 2025: Zynerba Pharmaceuticals is at the Forefront with Its Clinical-stage Therapy Zygel (ZYN002)
Fragile X Syndrome Therapeutic Pipeline Research Report 2024 Featuring Zynerba, Tetra Discovery Partners, Nova Mentis, Neuren Pharmaceuticals, and Tetra Discovery Partners
Why Shares of Harmony Bioscience Are Falling on Friday
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE
Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023
HARMONY BIOSCIENCES ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE
ZYNERBA PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Zynerba Pharmaceuticals, Inc. - ZYNE
Why Is Zynerba Pharmaceuticals (ZYNE) Stock Up 270% Today?
Zynerba Pharma stock rockets on premium priced Harmony deal
Harmony Biosciences to buy Zynerba Pharmaceuticals for up to $200 million
ZYNE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Zynerba Pharmaceuticals, Inc. Is Fair to Shareholders
HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting
Zynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock?
Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference
Zynerba Pharmaceuticals to Present at the Oppenheimer 33rd Annual Healthcare Conference
Zynerba Pharmaceuticals to Present at the Cowen 43rd Annual Health Care Conference